All In Biotech

Drug Trial Radar · NCT07943585

A Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Trial to Evaluate the Immunogenicity and Safety of a 24-Valent Pneumococcal Conjugate Vaccine (PCV24, RZ700) Following Vaccination in Adults Aged 18 Years and Older

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,260 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,260

Planned (sponsor's estimate)

Start

Nov 24, 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Reinovax Biologics Co., LTDIndustry
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase III clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.The study's objective is to evaluate the safety and immunogenicity of PCV24. The trial is a multicenter, randomized, double-blind and active-controlled phase III clinical trial.

Conditions

  • Pneumococcal Infectious Disease

Interventions

  • Prevention of pneumococcal disease from 24 serotypes with the administration of Reinovax's PCV24Biological

    Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL

  • PPSV23Biological

    One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and 33F polysaccharides.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).Time frame: 0~30 days after vaccination
  2. Proportional participants with the MOPA titer rise of 4-fold or higherTime frame: 0~30 days after vaccination
  3. Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).Time frame: 0~30 days after vaccination
  4. Incidence of adverse eventsTime frame: 0-30 minutes after vaccination
  5. Incidence of solicited adverse eventsTime frame: 0-7 days after vaccination
  6. Incidence of unsolicited adverse eventsTime frame: 0-30 days after vaccination
  7. Incidence of serious adverse events (SAE)Time frame: 0-6 months after vaccination

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Center for Disease Control and Prevention

    Shanghai, China

  • Hunan Center for Disease Control and Prevention

    Changsha, Hunan, China

  • Baoshan Second People's Hospital

    Baoshan, Yunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.